ASCO Annual Meeting | Conference

More Evidence for 10-Years of Tamoxifen in ER+ Breast Cancer

June 3rd 2013

A British study has confirmed that 10 years of adjuvant tamoxifen substantially reduces late breast cancer recurrence and mortality among women with estrogen receptor-positive disease.

Dr. Gilbert Describes Ongoing RTOG 0825 Trial Analyses

June 3rd 2013

Mark R. Gilbert, MD, from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.

Bevacizumab Improves Survival in Advanced Cervical Cancer

June 3rd 2013

Bevacizumab combined with either of two chemotherapy backbones improved overall survival by 3.7 months versus chemotherapy alone in patients with advanced cervical cancer.

Dr. Ribas on Anti-PD-1 Agent Lambrolizumab in Melanoma

June 3rd 2013

Antoni Ribas, MD, PhD, from UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.

Dr. Ramalingam Reviews the GALAXY-1 Trial Results

June 3rd 2013

Suresh S. Ramalingam, MD, from the Winship Cancer Institute, describes results from the phase II GALAXY-1 trial that explored the Hsp90 inhibitor ganetespib as a second-line treatment for patients with advanced lung adenocarcinoma.

Sorafenib Doubles PFS in Rare Thyroid Cancer

June 3rd 2013

Interim findings from a randomized, global, phase III study indicate that the multi-targeted drug sorafenib nearly doubled PFS for patients with differentiated thyroid cancer resistant to radioactive iodine therapy.

First-Line Bevacizumab Does Not Improve Survival in Glioblastoma

June 2nd 2013

Adding bevacizumab to a standard treatment regimen for glioblastoma consisting of chemoradiation with temozolomide in newly diagnosed patients does not improve OS and did not significantly improve PFS.

Richard Gray on a Longer Duration of Tamoxifen

June 2nd 2013

Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.

Dr. Brose on Sorafenib in RAI-Resistant Thyroid Cancer

June 2nd 2013

Marcia Brose, MD, PhD, from the Abramson Cancer Center at the University of Pennsylvania, discusses the phase III DECISION study that explored sorafenib in radioactive iodine-resistant differentiated thyroid cancer.

GM-CSF Boosts Ipilimumab Efficacy in Metastatic Melanoma

June 2nd 2013

Adding the white blood cell booster granulocyte-macrophage colony-stimulating factor to the immunotherapy ipilimumab extended survival in patients with metastatic melanoma when compared with ipilimumab alone and may be a safer alternative than monotherapy.

Dr. Heinemann Reviews the FIRE-3 Trial Results

June 2nd 2013

Volker Heinemann, MD, PhD, from the University of Munich, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.

Partners of HPV-Positive Oropharyngeal Cancer Patients Not at Increased Risk of HPV Infection or Oral Cancer

June 2nd 2013

Patients with human papilloma virus–positive oropharyngeal cancer and their spouses may find some reassurance in a study that found that partners are no more likely to be infected by HPV than the general population.

Maintenance Therapy With Pazopanib Delays Relapse of Advanced Ovarian Cancer

June 2nd 2013

An oral targeted drug already approved by the FDA for the treatment of kidney cancer and soft tissue sarcoma has been found to extend disease-free survival in women with advanced ovarian cancer.

Dr. Tewari on Bevacizumab in Advanced Cervical Cancer

June 2nd 2013

Krishnansu S. Tewari, MD, from the University of California Irvine in Orange, California, discusses the effectiveness of bevacizumab in relapsed and metastatic cervical cancer.

Cetuximab OS Results Top Bevacizumab in mCRC

June 2nd 2013

Frontline cetuximab plus FOLFIRI chemotherapy improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wild-type metastatic colorectal cancer.

Nivolumab Delivers Enduring Benefits in Advanced Melanoma

June 2nd 2013

Nivolumab has demonstrated an overall objective response rate of 31% with a median duration of two years in patients with advanced melanoma.

Dr. Sznol Describes Nivolumab in Advanced Melanoma

June 2nd 2013

Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from an expanded phase I study investigating the anti-PD-1 drug nivolumab in patients with advanced melanoma.

Dr. D'Souza on Spouses of HPV-Positive Patients

June 1st 2013

Gypsyamber D‘Souza, PhD, MPH, MS, from Johns Hopkins University, discusses the prevalence of oral HPV infections in the spouses of patients with HPV-positive oropharyngeal cancer.

Dr. du Bois on Pazopanib in Advanced Ovarian Cancer

June 1st 2013

Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

Dr. Carvajal Describes MEK Inhibition in Uveal Melanoma

June 1st 2013

Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition in patients with advanced uveal melanoma using the agent selumetinib.

NEXT PAGE
PREVIOUS PAGE